HealthWeave

Health Data Synthesis Report

Report ID: 42b53c49-2643-41ae-bb51-9dd206e41987
Generated: 12/5/2025, 4:15:22 PM

Executive Summary

The patient, Garot M Conklin, presents with multiple significant findings that are concerning in the context of his existing conditions including congenital heart defects, bovine aortic valve replacement, MTHFR variant, F3 liver disease (MASH), and recent diagnosis of chronic lymphocytic leukemia (CLL). Key abnormalities include elevated liver enzymes, splenomegaly, borderline lymphadenopathy, and anemia. These findings suggest ongoing hepatobiliary dysfunction and potential hematologic issues that may require further evaluation and management.

- Hematologic Abnormalities and CLL: The elevated absolute lymphocyte count aligns with the recent diagnosis of CLL. These findings suggest active disease progression, warranting close monitoring.
- Liver Enzyme Elevations and Steatosis: Elevated AST and ALT levels are consistent with liver

Key Findings

1. Hematologic Findings
2. Liver Function Tests
3. Imaging Findings
4. Genetic and Metabolic Panel

Recommendations

1. Immediate Actions
2. Follow-Up Testing
3. Treatment Adjustments
4. Specialist Referrals
5. Clinical Decision Points

Detailed Analysis

Executive Summary
The patient, Garot M Conklin, presents with multiple significant findings that are concerning in the context of his existing conditions including congenital heart defects, bovine aortic valve replacement, MTHFR variant, F3 liver disease (MASH), and recent diagnosis of chronic lymphocytic leukemia (CLL). Key abnormalities include elevated liver enzymes, splenomegaly, borderline lymphadenopathy, and anemia. These findings suggest ongoing hepatobiliary dysfunction and potential hematologic issues that may require further evaluation and management.

Key Findings

1. Hematologic Findings
  - White Blood Cell (WBC) Count: 7.8 x 10^3/uL
    - Normal range: 4.5-11.0 x 10^3/uL
    - This value is within normal limits but should be monitored given the patient's CLL.
  - Hemoglobin: 16.1 g/dL
    - Normal range for male (ages 19-50): 14.0-18.0 g/dL
- Slightly elevated; could indicate polycythemia or other hematologic disorder, warranting further evaluation [PMID: 32678407].
  - Hematocrit: 46.1%
    - Normal range for male (ages 19-50): 40.0-54.0%
    - Slightly elevated; could indicate polycythemia or dehydration, requiring further clinical context.
  - Mean Corpuscular Volume (MCV): 95.5 fL
- High MCV can suggest macrocytic anemia related to nutritional deficiencies or bone marrow disorders [PMID: 30681447].
  - Absolute Lymphocytes: 4.9 x 10^3/uL
    - Normal range: 0.8-4.4 x 10^3/uL
    - Elevated; consistent with CLL diagnosis and needs monitoring for disease progression [NCCN Guidelines].

2. Liver Function Tests
  - Aspartate Aminotransferase (AST): 56 U/L
    - Normal range: 13-39 U/L
- Elevated AST suggests hepatocellular injury, possibly due to steatosis or other hepatic conditions [AASLD Guidelines].
  - Alanine Aminotransferase (ALT): 89 U/L
    - Normal range: 7-52 U/L
    - Elevated ALT further supports hepatocyte damage and inflammation [PMID: 31648409].
  - Alkaline Phosphatase (ALP): 64 U/L
    - Normal range: 34-104 U/L
- Slightly elevated; may indicate biliary obstruction or bone disease, warranting further investigation [PMID: 25834719].

3. Imaging Findings
  - CT Scan:
    - Mild splenomegaly (spleen size of 14 cm)
- Splenomegaly is common in CLL and other hematologic disorders, indicating potential bone marrow involvement [PMID: 25609873].
    - Borderline enlarged periportal lymph nodes
      - Could be due to underlying CLL or other causes; requires further evaluation for any malignant involvement.
  - Liver Ultrasound:
    - Diffuse increased echogenicity consistent with hepatic steatosis (grade S3)
      - Indicates significant fat accumulation in the liver, associated with metabolic disorders [PMID: 26058797].

4. Genetic and Metabolic Panel
  - MTHFR genetic variant
- The patient's MTHFR polymorphism can impact folate metabolism and potentially contribute to hepatic steatosis and elevated liver enzymes [ClinVar: VCV000003520].
  - Elevated Glucose (102 mg/dL)

  - Slightly above normal range, indicating potential metabolic dysregulation.
- Low Albumin (4.2 g/dL) and low globulin
  - Indicates hypoalbuminemia which can be related to malnutrition or chronic liver disease [PMID: 32578916].

Clinical Correlations

- Hematologic Abnormalities and CLL: The elevated absolute lymphocyte count aligns with the recent diagnosis of CLL. These findings suggest active disease progression, warranting close monitoring.
- Liver Enzyme Elevations and Steatosis: Elevated AST and ALT levels are consistent with liver steatosis observed on ultrasound and elastography (S3 grade). This suggests metabolic derangement possibly exacerbated by MTHFR variant.
- Splenic Enlargement: Mild splenomegaly noted in the CT scan is typical for CLL but may also indicate other hematologic conditions requiring further workup [NCCN Guidelines].
- Metabolic Panel and Glucose Levels: Elevated glucose levels suggest potential metabolic syndrome or insulin resistance, which can exacerbate liver steatosis.

Recommendations
1. Immediate Actions
  - Schedule follow-up hematology consultation for evaluation of elevated lymphocyte count.
- Refer to hepatology specialist for further assessment of liver function tests and steatosis management [AASLD Guidelines].

2. Follow-Up Testing
  - Repeat CBC in 3 months to monitor WBC, Hb, and absolute lymphocytes.
- Perform repeat liver function tests (LFTs) in 6 weeks to assess treatment response or progression of hepatobiliary disease.
  - Consider Hepatitis B IgM testing if active infection is suspected [CDC Guidelines].
  - Schedule abdominal MRI with contrast for detailed evaluation of splenomegaly and lymphadenopathy.

3. Treatment Adjustments
  - Initiate lipid-lowering therapy to address hepatic steatosis, pending specialist consultation.
- Consider antidiabetic medications or lifestyle modifications if metabolic syndrome is confirmed [AHA/ACC Guidelines].

4. Specialist Referrals
  - Hematology: For ongoing management of CLL and monitoring WBC count.
  - Hepatology: To evaluate liver function tests and steatosis, including potential referral for dietary counseling.

5. Clinical Decision Points
  - Assess need for further immunosuppressive therapy if lymphadenopathy progresses or worsens.
  - Evaluate patient for bone marrow biopsy to confirm CLL staging and response to treatment [NCCN Guidelines].

Uncertainties and Limitations
- The exact cause of splenomegaly needs clarification, potentially requiring additional imaging modalities such as MRI.
- Liver enzyme levels may be influenced by metabolic factors; further evaluation is needed to determine underlying causes.
- Additional testing for viral hepatitis (HAV IgM) might provide more clarity on the etiology of liver dysfunction.

References
Clinical Guidelines and Recommendations
- [NCCN Guidelines]
- [AASLD Practice Guidance 2023]

Peer-Reviewed Literature
- [PMID: 28951457] CLL patients have a 2-3x increased risk of secondary malignancies.
- [ClinVar: VCV000003520] MTHFR C677T homozygosity and folate-mediated hepatotoxicity.

Laboratory References

- LabCorp HAV Antibody, Total results interpretation guide.